ClinicalTrials.Veeva

Menu

High Dose CHOP in Lymphoma

R

Rambam Health Care Campus

Status and phase

Completed
Phase 2

Conditions

Non-Hodgkin's Lymphoma

Treatments

Drug: high-dose cyclophosphamide

Study type

Interventional

Funder types

Other

Identifiers

NCT00192764
RonHDCHOP.CTIL

Details and patient eligibility

About

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • large-cell non-Hodgkin's lymphoma
  • IPI low-intermediate, high-intermediate and high or bulky mediastinum
  • age 18-65

Exclusion criteria

  • previous treatment for lymphoma
  • serious concurrent systemic disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems